This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Genzyme's performance against key rivals in the prescription pharmaceutical sector
*See how the company's core products of Cerezyme, Fabrazyme and Myozyme/Lumizyme will continue to act as the primary sales growth drivers
*Assess the impact of the recent contamination of the Allston manufacturing facility on the company's performance through 2009
Table of Contents :
ABOUT HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company Introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 8
Genzyme: PharmaVitae forecasts at a glance 9
Strategic insight 10
Genzyme success in ultra-niche markets 10
Combination of fast revenue growth and margin improvement leads to explosive profit growth 10
With the blockbuster model under threat, Genzyme's niche market strategy looks set to hold firm 11
High-risk blockbuster model out-dated? 11
Genzyme's niche market-targeting an alternative strategy 11
Greater economies of scale as rare genetic disorders franchise expands 12
For more information please contact :http://www.aarkstore.com/reports/Genzyme-Corporation-PharmaVitae-Profile-18483.html
